{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:07:00Z","timestamp":1791979620238,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10096-023-04671-0","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T01:02:12Z","timestamp":1697158932000},"page":"1395-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Extreme resistance to the novel siderophore-cephalosporin cefiderocol in an extensively drug-resistant Klebsiella pneumoniae strain causing fatal pneumonia with sepsis: genomic analysis and synergistic combinations for resistance reversal"],"prefix":"10.1007","volume":"42","author":[{"given":"Land","family":"Daoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushal","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Collyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akela","family":"Ghazawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqeel","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5711-6264","authenticated-orcid":false,"given":"Farah","family":"Al-Marzooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"69","key":"4671_CR1","doi-asserted-by":"publisher","first-page":"S538","DOI":"10.1093\/cid\/ciz826","volume":"13","author":"T Sato","year":"2019","unstructured":"Sato T, Yamawaki K (2019) Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis 13(69):S538\u2013S543. https:\/\/doi.org\/10.1093\/cid\/ciz826","journal-title":"Clin Infect Dis"},{"issue":"72","key":"4671_CR2","doi-asserted-by":"publisher","first-page":"e1103","DOI":"10.1093\/cid\/ciaa1799","volume":"15","author":"S Naseer","year":"2021","unstructured":"Naseer S, Weinstein EA, Rubin DB, Suvarna K, Wei X, Higgins K et al (2021) US Food and Drug Administration (FDA): benefit-risk considerations for cefiderocol (Fetroja\u00ae). Clin Infect Dis 15(72):e1103\u2013e1111. https:\/\/doi.org\/10.1093\/cid\/ciaa1799","journal-title":"Clin Infect Dis"},{"issue":"62","key":"4671_CR3","doi-asserted-by":"publisher","first-page":"e01454","DOI":"10.1128\/AAC.01454-17","volume":"21","author":"A Ito","year":"2017","unstructured":"Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S et al (2017) In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother 21(62):e01454-e1517. https:\/\/doi.org\/10.1128\/AAC.01454-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"73","key":"4671_CR4","doi-asserted-by":"publisher","first-page":"e4472","DOI":"10.1093\/cid\/ciaa1909","volume":"6","author":"AP Streling","year":"2021","unstructured":"Streling AP, Al Obaidi MM, Lainhart WD, Zangeneh T, Khan A, Dinh AQ et al (2021) Evolution of cefiderocol non-susceptibility in Pseudomonas aeruginosa in a patient without previous exposure to the antibiotic. Clin Infect Dis 6(73):e4472\u2013e4474. https:\/\/doi.org\/10.1093\/cid\/ciaa1909","journal-title":"Clin Infect Dis"},{"issue":"27","key":"4671_CR5","doi-asserted-by":"publisher","first-page":"2200795","DOI":"10.2807\/1560-7917.ES.2022.27.43.2200795","volume":"27","author":"M Coppi","year":"2022","unstructured":"Coppi M, Antonelli A, Niccolai C, Bartolini A, Bartolini L, Grazzini M et al (2022) Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022. Euro Surveill 27(27):2200795. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.43.2200795","journal-title":"Euro Surveill"},{"key":"4671_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","volume":"11","author":"S Karakonstantis","year":"2022","unstructured":"Karakonstantis S, Rousaki M, Kritsotakis EI (2022) Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics 11:723. https:\/\/doi.org\/10.3390\/antibiotics11060723","journal-title":"Antibiotics"},{"issue":"17","key":"4671_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277946","volume":"29","author":"L Daoud","year":"2022","unstructured":"Daoud L, Al-Marzooq F, Moubareck CA, Ghazawi A, Collyns T (2022) Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol. PLoS ONE 29(17):e0277946. https:\/\/doi.org\/10.1371\/journal.pone.0277946","journal-title":"PLoS ONE"},{"key":"4671_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijantimicag.2018.03.003","volume":"52","author":"CA Moubareck","year":"2018","unstructured":"Moubareck CA, Mouftah SF, P\u00e1l T, Ghazawi A, Halat DH, Nabi A et al (2018) Clonal emergence of Klebsiella pneumoniae ST14 co-producing OXA-48-type and NDM carbapenemases with high rate of colistin resistance in Dubai, United Arab Emirates. Int J Antimicrob Agents 52:90\u201395. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.03.003","journal-title":"Int J Antimicrob Agents"},{"key":"4671_CR9","doi-asserted-by":"publisher","first-page":"e03496","DOI":"10.1128\/spectrum.03496-22","volume":"25","author":"SH Moon","year":"2023","unstructured":"Moon SH, Huang E (2023) Cefiderocol resistance in Klebsiella pneumoniae is linked to SHV extended-spectrum \u03b2-lactamase activities and functional loss of the outer membrane porin OmpK35. Microbiol Spectr 25:e03496-e3522. https:\/\/doi.org\/10.1128\/spectrum.03496-22","journal-title":"Microbiol Spectr"},{"key":"4671_CR10","doi-asserted-by":"publisher","unstructured":"Lan P, Lu Y, Chen Z, Wu X, Hua X, Jiang Y et al (2022) Emergence of high-level cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in patients with hematologic malignancies in China. Microbiol Spectr 0:e00084\u201322. https:\/\/doi.org\/10.1128\/spectrum.00084-22","DOI":"10.1128\/spectrum.00084-22"},{"issue":"12","key":"4671_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.875116","volume":"27","author":"C Shankar","year":"2022","unstructured":"Shankar C, Vasudevan K, Jacob JJ, Baker S, Isaac BJ, Neeravi AR et al (2022) Hybrid plasmids encoding antimicrobial resistance and virulence traits among hypervirulent Klebsiella pneumoniae ST2096 in India. Front Cell Infect Microbiol 27(12):875116. https:\/\/doi.org\/10.3389\/fcimb.2022.875116","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"4671_CR12","doi-asserted-by":"publisher","first-page":"e00673","DOI":"10.1128\/spectrum.00673-22","volume":"28","author":"S Takei","year":"2022","unstructured":"Takei S, Lu YJ, Tohya M, Watanabe S, Misawa S, Tabe Y et al (2022) Spread of carbapenem-resistant Klebsiella pneumoniae clinical isolates producing NDM-Type metallo-\u03b2-lactamase in Myanmar. Microbiol Spectr 28(10):e00673-e722. https:\/\/doi.org\/10.1128\/spectrum.00673-22","journal-title":"Microbiol Spectr"},{"key":"4671_CR13","doi-asserted-by":"publisher","unstructured":"Simner PJ, Bergman Y, Conzemius R, Jacobs E, Tekle T, Beisken S et al (2023) An NDM-producing Escherichia coli clinical isolate exhibiting resistance to cefiderocol and the combination of ceftazidime-avibactam and aztreonam: another step towards pan-\u03b2-lactam resistance. Open Forum Infect Dis ofad276. https:\/\/doi.org\/10.1093\/ofid\/ofad276","DOI":"10.1093\/ofid\/ofad276"},{"issue":"66","key":"4671_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02011-21","volume":"1","author":"D Nurjadi","year":"2022","unstructured":"Nurjadi D, Kocer K, Chanthalangsy Q, Klein S, Heeg K, Boutin S (2022) New Delhi metallo-beta-lactamase facilitates the emergence of cefiderocol resistance in Enterobacter cloacae. Antimicrob Agents Chemother 1(66):e0201121. https:\/\/doi.org\/10.1128\/aac.02011-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"93","key":"4671_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijid.2020.02.005","volume":"1","author":"A Khalid","year":"2020","unstructured":"Khalid A, Lubi\u00e1n AF, Ma L, Lin RCY, Iredell JR (2020) Characterizing the role of porin mutations in susceptibility of beta lactamase producing Klebsiella pneumoniae isolates to ceftaroline and ceftaroline-avibactam. Int J Infect Dis 1(93):252\u2013257. https:\/\/doi.org\/10.1016\/j.ijid.2020.02.005","journal-title":"Int J Infect Dis"},{"issue":"62","key":"4671_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106917","volume":"1","author":"X Vuillemin","year":"2023","unstructured":"Vuillemin X, Da Silva M, Bour M, Landon C, Pl\u00e9siat P, Jeannot K (2023) Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa. Int J Antimicrob Agents 1(62):106917. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106917","journal-title":"Int J Antimicrob Agents"},{"issue":"27","key":"4671_CR17","doi-asserted-by":"publisher","first-page":"1172.e7","DOI":"10.1016\/j.cmi.2021.04.016","volume":"1","author":"CA Hobson","year":"2021","unstructured":"Hobson CA, Cointe A, Jacquier H, Choudhury A, Magnan M, Courroux C et al (2021) Cross-resistance to cefiderocol and ceftazidime\u2013avibactam in KPC \u03b2-lactamase mutants and the inoculum effect. Clin Microbiol Infect 1(27):1172.e7-1172.e10. https:\/\/doi.org\/10.1016\/j.cmi.2021.04.016","journal-title":"Clin Microbiol Infect"},{"issue":"52","key":"4671_CR18","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ijantimicag.2018.11.005","volume":"1","author":"L Poirel","year":"2018","unstructured":"Poirel L, Kieffer N, Nordmann P (2018) Stability of cefiderocol against clinically significant broad-spectrum oxacillinases. Int J Antimicrob Agents 1(52):866\u2013867. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.005","journal-title":"Int J Antimicrob Agents"},{"key":"4671_CR19","doi-asserted-by":"publisher","unstructured":"Poirel L, Ortiz de la Rosa J-M, Sadek M, Nordmann P (2022) Impact of acquired broad-spectrum \u03b2-lactamases on susceptibility to cefiderocol and newly developed \u03b2-lactam\/\u03b2-lactamase inhibitor combinations in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 66:e00039\u201322. https:\/\/doi.org\/10.1128\/aac.00039-22","DOI":"10.1128\/aac.00039-22"},{"issue":"71","key":"4671_CR20","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/cid\/ciaa355","volume":"1","author":"RK Shields","year":"2020","unstructured":"Shields RK, Iovleva A, Kline EG, Kawai A, McElheny CL, Doi Y (2020) Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime. Clin infect dis 1(71):2713\u20132716. https:\/\/doi.org\/10.1093\/cid\/ciaa355","journal-title":"Clin infect dis"},{"issue":"14","key":"4671_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2147\/IDR.S298515","volume":"3","author":"Y Han","year":"2021","unstructured":"Han Y, Huang L, Liu C, Huang X, Zheng R, Lu Y et al (2021) Characterization of carbapenem-resistant Klebsiella pneumoniae ST15 clone coproducing KPC-2, CTX-M-15 and SHV-28 spread in an intensive care unit of a tertiary hospital. IDR 3(14):767\u2013773. https:\/\/doi.org\/10.2147\/IDR.S298515","journal-title":"IDR"},{"issue":"71","key":"4671_CR22","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/cid\/ciz1159","volume":"15","author":"RK Shields","year":"2020","unstructured":"Shields RK, Doi Y (2020) Aztreonam combination therapy: an answer to metallo-\u03b2-lactamase\u2013producing gram-negative bacteria? Clin infect dis 15(71):1099\u20131101. https:\/\/doi.org\/10.1093\/cid\/ciz1159","journal-title":"Clin infect dis"},{"issue":"13","key":"4671_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.959107","volume":"15","author":"X Li","year":"2022","unstructured":"Li X, Zhao J, Zhang B, Duan X, Jiao J, Wu W et al (2022) Drug development concerning metallo-\u03b2-lactamases in gram-negative bacteria. Front microbiol 15(13):959107. https:\/\/doi.org\/10.3389\/fmicb.2022.959107","journal-title":"Front microbiol"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04671-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-023-04671-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04671-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T12:04:24Z","timestamp":1697717064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-023-04671-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["4671"],"URL":"https:\/\/doi.org\/10.1007\/s10096-023-04671-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval to conduct the study was received from Tawam Human Research Ethics Committee, Al-Ain, UAE (approval number: MF2058-2021\u2013761).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}